Pedro-Botet Juan, Climent Elisenda, Benaiges David
Unidad de Lípidos y Riesgo Vascular, Servicio de Endocrinología y Nutrición, Hospital del Mar, Universidad Autónoma de Barcelona, Barcelona, España.
Unidad de Lípidos y Riesgo Vascular, Servicio de Endocrinología y Nutrición, Hospital del Mar, Universidad Autónoma de Barcelona, Barcelona, España.
Med Clin (Barc). 2020 Sep 25;155(6):256-262. doi: 10.1016/j.medcli.2020.04.024. Epub 2020 Jun 20.
The recognition of atherogenesis as an active process rather than a passive cholesterol storage disease has underlined key inflammatory mechanisms. Hence, innate and adaptive immune responses play an important role in the onset and progression of atherosclerosis. More recently, some clinical studies were designed to address the impact of anti-inflammatory intervention strategies in reducing risk of cardiovascular disease beyond the management of classic risk factors. Therefore, we review first the pathophysiological contribution of inflammation to atherosclerosis and the effect of lipid-lowering drugs on inflammatory biomarkers. Next, we address the effect of classic anti-inflammatory drugs, pharmacological therapies targeting specific inflammatory mediators and vaccines in cardiovascular prevention.
将动脉粥样硬化的形成视为一个主动过程而非被动的胆固醇储存疾病,这凸显了关键的炎症机制。因此,先天性和适应性免疫反应在动脉粥样硬化的发生和发展中起着重要作用。最近,一些临床研究旨在探讨抗炎干预策略在降低心血管疾病风险方面的作用,而不仅仅是控制经典危险因素。因此,我们首先回顾炎症对动脉粥样硬化的病理生理贡献以及降脂药物对炎症生物标志物的影响。接下来,我们讨论经典抗炎药物、针对特定炎症介质的药物治疗以及疫苗在心血管预防中的作用。